Valbiotis Completes Recruitment for Cardio-Liver Study with TOTUM•448

Valbiotis has announced the successful completion of participant recruitment for its Cardio-Liver clinical study. This study involves TOTUM•448, a dietary supplement intended for metabolic liver diseases (MASLD). A total of 70 volunteers have been randomized in this double-blind, placebo-controlled trial.

Conducted alongside Laval University, the study aims to evaluate TOTUM•448's impact on various risk factors associated with early MASLD stages. Results are expected in the latter half of 2026. The trial also explores cardiometabolic and inflammatory parameters, promising a comprehensive insight into MASLD pathophysiology.

Upon market launch, TOTUM•448 will capitalize on established commercialization infrastructures in France and joint ventures in Asia. This aligns with Valbiotis’ strategy to address the significant global market of metabolic liver disease prevention.